| Development of Original and Innovative New Drugs, in Japan, Europe and the US | ||
|
Patients suffering from disease are found in all corners of the globe. It is Ono's earnest
desire to deliver to patients worldwide original and innovative new drugs that fulfill
the needs found at the frontline of healthcare. This has led to the marketing of many prostaglandins
and enzyme inhibitors. In clinical development, we aim to achieve speedy confirmation of
the efficacy and safety of original and innovative new drug candidate compounds. In our three bases
in Japan, Europe and the US, we conduct development on drugs to treat many diseases.
Our hope is to deliver a new drug as quickly as possible into the hands of patients who are suffering
from the ravages of a disease that has yet to be conquered. We endeavor to increase the likelihood
of success by conducting clinical trials based on our knowledge of the properties of the compounds.
Based on the mechanism of action of compounds under development, we conduct trials on patients for
whom greater efficacy seems more promising.
Outside Japan, work is not restricted to development projects pursued by Ono alone. We promote clinical trials that are being conducted by bio-pharmaceutical companies. |
||
| Global Clinical Development | ||
|
As Ono's aim is to develop new drugs to global standards, our top priority is gaining approval
in Europe and the US. We actively pursue leading clinical development overseas. To achieve success
in clinical development, the development plan holds an extremely important key.
Some fifty development staff in Japan are engaged in formulating the development plan (planning). Meanwhile, roughly one hundred members of our development staff in Japan monitor clinical development in Japan to ensure speedy and high-quality development. In the US, the Global Development Headquarters was established within Ono Pharma USA (OPUS) in May 2008, epitomizing the effort to strengthen our international clinical development system centering on the United Sates. Currently, OPUS has approximately thirty Japanese and local staff engaged in clinical development. In Europe, Ono Pharma UK Ltd. (OPUK) currently has roughly ten staff members engaged in clinical development. As we expect the number of projects both in Japan and overseas to increase, we are ready to strengthen our clinical development system by employing more local staff as necessary. |